Antonio Calles
Enriched profileHead of the Lung Cancer Unit, Hospital Ruber Internacional (Quirónsalud), Madrid · Hospital Ruber Internacional (Quirónsalud)
Antonio Calles is Head of the Lung Cancer Unit, Hospital Ruber Internacional (Quirónsalud), Madrid at Hospital Ruber Internacional (Quirónsalud). OpenAlex indexes 211 publications with 4,535 citations (h-index 36); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 9 Nov 2026
Overview
Updated 11 Nov 2026
Antonio Calles is Head of the Lung Cancer Unit, Hospital Ruber Internacional (Quirónsalud), Madrid. The public record shows 211 publications with 4,535 citations (h-index 36), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies. It also documents an investigator role on 5 registered clinical trials.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer Treatments and Mutations
- 5 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 11 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. 16 in PubMed. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 70.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
No public contact details on file. Research profiles have no U.S. clinical registration, so there's no federal registry record to draw an address or phone from. Why? →
Clinical trials
Updated 9 Nov 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Sponsor: Nuvalent Inc.
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 9 Nov 2026
58 congress contributions (2011–2026) across AACR, AHA, ASCO, ESMO, IASLC, ISPOR Europe per OpenAlex. The most recent:
- Abstract 2434: Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET -rearranged advanced NSCLC
AACR Annual Meeting
AACR2026Co-author - Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 9 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.
Journal of clinical oncology
Article2026 - Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.
Cancer communications (London, England)
Clinical Trial2025 - Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.
Molecular cancer therapeutics
Review2025
Online presence
Updated 9 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/antonio-calles-776b8145
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 9 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Medical degree
Universidad Autónoma de Madrid
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →comunidad.madrid ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →comunidad.madrid ↗
Editorial & leadership roles
journal and society appointments- Associate Editor
Frontiers (journal section not confirmed; listed as Associate Editor for Thoracic Oncology on Frontiers Oncology editors page)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →theorg.com ↗ - Faculty member
Lung and other Thoracic Tumours group, European Society for Medical Oncology (ESMO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →quironsalud.com ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dev.lungsummit.org ↗
- Hospital General Universitario Gregorio Marañón: Médico Especialista en Oncología Médica
Unidad de tumores torácicos
2019provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →comunidad.madrid ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →quironsalud.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Ignacio Wistuba, MD
Moffitt Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)